Metrix Partners expands its footprint in life sciences and adds Zymvol to its client list

Zymvol joined the Metrix Partners client list in March 2023, expanding the firm’s life sciences practice. Zymvol specialises in computational engineering for enzyme discovery and optimisation.

Zymvol joins Metrix Partners life sciences practice

About Zymvol

Zymvol uses computer simulation to design and improve enzymes, the biological catalysts used in pharmaceutical, chemical and food manufacturing. Computational design addresses several problems in traditional discovery and development: time to market, the sustainability of manufacturing processes and the ability to recycle polymers.

The company raised a seed round led by Elaia Partners, reported by El Referente, and became one of the newest tenants of the Barcelona Science Park. Both traditional pharma and the chemical industry can benefit from its science.

The Metrix life sciences practice

Metrix has worked with life sciences companies for many years. The practice covers therapeutics, diagnostics, medical devices and industrial biotech. Life sciences companies have finance needs that differ from software startups:

  • Long development timelines before revenue, often five years or more.
  • Heavy use of public grants and loans alongside venture capital.
  • Milestone-based budgets tied to research, clinical and regulatory steps.
  • Partnering and licensing deals with large pharma or industrial groups.
  • Complex reporting to several funders with different rules.

Five finance lessons for life sciences startups

  1. Plan by milestone, not by year. Investors fund the next value inflection point. The budget should show the cost of reaching each one.
  2. Track grants carefully. Public funding comes with eligible cost rules, audits and reporting deadlines. Errors can lead to repayment.
  3. Capitalise R&D correctly. Accounting choices on development costs affect equity and must follow clear criteria.
  4. Value partnership deals properly. Upfront payments, milestones and royalties have different accounting and tax treatment.
  5. Keep the cap table clean. Research institutions, angels and public investors can create complex ownership structures.

What Metrix provides to life sciences clients

  • Fractional CFO services and management reporting.
  • Non-dilutive funding applications and grant management.
  • Fundraising support and investor due diligence preparation.
  • Financial models for development programmes and partnering deals.
  • M&A advice on licensing, partnerships and company sales.

Why industrial biotech is growing

Chemical and pharmaceutical manufacturers are under pressure to cut energy use, waste and emissions. Biological processes based on enzymes can replace harsh chemical steps, but finding the right enzyme by laboratory screening alone is slow and costly. Computational tools that narrow the search before any experiment shorten development and reduce cost, which is why investors with a technology focus, such as Elaia, back the sector.

Track record in life sciences

Metrix has advised life sciences companies through financing and exits, including Northern Biologics and its deal with AstraZeneca, Aelix Therapeutics, Ona Therapeutics, DeepUll and VB Devices. For Zymvol, Metrix also advised Elaia Partners on its seed investment.